Glutaminase inhibitor CB-839 causes metabolic adjustments in colorectal cancer cells

Abstract Colorectal cancer (CRC) cells are ‘addicted’ to glutamine to satisfy energy and biosynthetic needs. Inhibiting glutamine metabolism enzymes, like glutaminase, is a potential cancer therapy strategy. Although the GLS inhibitor CB-839 is being evaluated in clinical trials, a comprehensive ass...

Descripción completa

Detalles Bibliográficos

Autores principales:	Martina Spada, Cristina Piras, Vera Piera Leoni, Mattia Casula, Gabriella Simbula, Antonio Noto, Katia Lilliu, Karolina Krystyna Kopeć, Gabriele Serreli, Federica Murgia, Federica Etzi, Tinuccia Dettori, Luigi Atzori, Paola Caria
Formato:	Artigo
Lenguaje:	Inglês
Publicado:	Nature Portfolio 2025-10-01
Colección:	Scientific Reports
Materias:	Colorectal cancer Glutamine metabolism CB-839 Glutaminolysis Glutaminase-1 inhibition Energetic metabolism
Acceso en línea:	https://doi.org/10.1038/s41598-025-20528-2
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!